The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA approval of CD19-targeted ADC, loncastuximab tesirine-Ipyl, for patients with R/R large B-cell lymphoma
On April 23, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of loncastuximab tesirine-lpyl, an antibody–drug conjugate (ADC), for the treatment of adult patients with relapsed and refractory (R/R) large B-cell lymphoma who have had ≥2 lines of therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high grade B-cell lymphoma.1 This approval was based on the results of the phase II LOTIS-2 trial (NCT03589469), previously reported on the Lymphoma Hub.
Loncastuximab tesirine-Ipyl is a CD19-targeted antibody and alkylating agent conjugate designed to target and kill CD19-expressing malignant B cells. LOTIS-2 is a single-arm, multicenter trial in 145 adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who received ≥2 prior lines of systemic therapy. Treatment with loncastuximab tesirine-Ipyl resulted in an overall response rate of 48.3% and a complete response rate of 24.1%. The median duration of response was 10.3 months. The most common Grade ≥3 treatment-emergent adverse events (in ≥10% of patients) included neutropenia (26.2%), thrombocytopenia (17.9%), increased gamma-glutamyltransferase (17.2%), and anemia (10.3%).
This approval is the first for an CD19-targeted ADC as single-agent therapy for R/R DLBCL.1
On May 5, 2021, loncastuximab tesirine-lpyl was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for the treatment of B-cell lymphomas. As a result, the agent now represents a category 2A treatment option for patients with DLBCL who have relapsed following ≥2 lines of systemic therapy.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content